For the year (end-December 31), Median had revenues of 23.8 million euros, up 16% compared with the 16.5 million euros produced in 2021. As of December 31, Median had a backlog of 60.8 million euros.

The company's revenue is generated "entirely" by the iCRO division's commercial activity, Median said in its financial report. Among the company's highlights from the past year include launching Imaging Lab to extract imaging data from cancer trials and initiating discussions with the U.S. Food and Drug Administration around obtaining clearance for its iBiopsy lung cancer screening software.